Englander Institute for Precision Medicine

Publications

Found 19 results
Author Title Type [ Year(Asc)]
Filters: Author is Hussain, Maha  [Clear All Filters]
2024
Shore ND, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Tombal B, Nordquist L, Cookson M, Verholen F et al..  2024.  Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.. Oncologist. 29(3):235-243.
2023
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, E Crawford D, Shore N, Kopyltsov E, Kalebasty ARezazadeh, Bögemann M et al..  2023.  Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.. J Clin Oncol. 41(20):3595-3607.
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M et al..  2023.  Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.. Eur Urol. 83(3):267-293.
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M et al..  2023.  Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.. Eur J Cancer. 185:178-215.
Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, De Giorgi U et al..  2023.  Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.. J Urol. 209(3):532-539.
Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, De Giorgi U et al..  2023.  Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide? Future Oncol. 19(29):1953-1960.
2022
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Manarite J, Muslin D, Farrington T, Tombal B.  2022.  Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.. Future Oncol. 18(21):2585-2597.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, E Crawford D, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á et al..  2022.  Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.. N Engl J Med. 386(12):1132-1142.
Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H et al..  2022.  Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.. Prostate Cancer Prostatic Dis. 25(2):288-295.
Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M et al..  2022.  Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.. Eur Urol. 82(1):115-141.
Joshua AM, Armstrong A, Crumbaker M, Scher HI, de Bono J, Tombal B, Hussain M, Sternberg CN, Gillessen S, Carles J et al..  2022.  Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.. Eur J Cancer. 170:285-295.
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M et al..  2022.  What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. Eur Urol. 82(1):6-11.
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J et al..  2022.  Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 18(35):3867-3874.
2021
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V et al..  2021.  Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.. Lancet Oncol. 22(4):525-537.
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J et al..  2021.  Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.. Eur J Cancer. 159:237-246.
Tombal B, Stenzl A, Cella D, Loriot Y, Armstrong AJ, Fizazi K, Beer T, Sternberg CN, Hussain M, Ivanescu C et al..  2021.  The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials.. Cancers (Basel). 13(23)
2020
Antonarakis ES, Velho PIsaacsson, Fu W, Wang H, Agarwal N, Santos VSacristan, Maughan BL, Pili R, Adra N, Sternberg CN et al..  2020.  -Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.. JCO Precis Oncol. 4:370-381.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP et al..  2020.  Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.. N Engl J Med. 382(23):2197-2206.
Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N et al..  2020.  Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.. Eur Urol. 77(4):508-547.